Cleveland Clinic-Led Trial Shows Cholesterol-Lowering Drug Reduces Heart-Related Events Including Death in Statin-Intolerant Patients with Elevated Cardiovascular Risk

Patients in primary prevention subgroup studied by global health system had risk factors but no pre-existing heart disease

Tuesday, July 11, 2023, Cleveland: Findings from a clinical trial led by global health system Cleveland Clinic showed that the use of bempedoic acid (a cholesterol-lowering drug) in statin intolerant patients who have not yet had a cardiovascular event, but do have risk factors, like diabetes, significantly reduced the chance of death from heart disease and other major adverse cardiovascular events such as heart attacks and strokes.

Continue reading Cleveland Clinic-Led Trial Shows Cholesterol-Lowering Drug →